Ignite Creation Date:
2024-05-06 @ 3:53 PM
Last Modification Date:
2024-10-26 @ 1:59 PM
Study NCT ID:
NCT04791098
Status:
RECRUITING
Last Update Posted:
2021-03-10
First Post:
2021-03-08
Brief Title:
Impact of Infectious Diseases Consultation on Vaccination Coverage Among People Waiting for a Kidney Transplant at the Clermont-Ferrand Hospital
Sponsor:
University Hospital Clermont-Ferrand
Organization:
University Hospital Clermont-Ferrand
Study Overview
Official Title:
Impact of Infectious Diseases Consultation on Vaccination Coverage Among People Waiting for a Kidney Transplant at the Clermont-Ferrand Hospital
Status:
RECRUITING
Status Verified Date:
2021-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PREVAGREF
Brief Summary:
Solid-organ transplant patients are at increased risk of infectious diseases Among this population infectious diseases may be life-threatening or lead to graft rejection Their prevention is an important challenge Despite specific national recommendations vaccination is underutilized That is why we propose a dedicated infectious diseases consultation during pre-kidney transplantation assessment
Detailed Description:
The main objective of this study is to impove vaccine coverage before kidney transplantation
Enrollment was based on the waiting list for a kidney transplant Patients newly listed are invited to participate by the transplant team nephrology department for those that are already registered a notification letter is sent to their home
All patients included must
complete a health questionnaire
take a blood test at day 0 viral bacterial and parasitic serologies QuantiFERON-TB
take a chest X-ray and dental panoramic Patients randomized in interventional group will be seen in specific infectious diseases consultation at Clermont Ferrand Hospital A letter of recommendations is sent to nephrologist for patients randomized in group control
The primary study endpoint immunization coverage is evaluated at 6 months
Enrollment was based on the waiting list for a kidney transplant Patients newly listed are invited to participate by the transplant team nephrology department for those that are already registered a notification letter is sent to their home
All patients included must
complete a health questionnaire
take a blood test at day 0 viral bacterial and parasitic serologies QuantiFERON-TB
take a chest X-ray and dental panoramic Patients randomized in interventional group will be seen in specific infectious diseases consultation at Clermont Ferrand Hospital A letter of recommendations is sent to nephrologist for patients randomized in group control
The primary study endpoint immunization coverage is evaluated at 6 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2019-A02304-53 | OTHER | ANSM | None |